The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study

摘要

Objective: The curative treatment approach for diffuse large B-cell lymphoma (DLBCL) is controversial even in the rituximab(R) era. The aim of this study was to examine the FcγRIIIA gene polymorphism distribution of DLBCL patients who hadbeen treated with R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Furthermore, weinvestigated the impact of FcγRIIIA gene polymorphism on the overall response rate (ORR) and overall survival (OS).Materials and Methods: Patients from 3 centers in the Aegean region of Turkey who had newly diagnosed CD20-positiveDLBCL were enrolled in the study. The single nucleotide polymorphisms of the FcγRIIIA gene were analyzed by real time-PCR. The response to treatment was determined in the middle and at the end of the protocol. During 2 years of follow-up, thepatients were clinically and radiologically evaluated for disease status every 3 months.Results: Thirty-six patients were included in the study and the distributions of F/F, V/F, and V/V types of alleles of FcγRIIIAwere 25%, 50%, and 25%, respectively. Twenty-seven patients were considered as evaluable according to ORR and OS. Thepatients’ ORR was 87.5%, 100%, and 50% in the F/F, V/F, and V/V allele groups, respectively. We did not establish anystatistically significant differences among the 3 alleles groups in respect to ORR (p=0.93). The OS within 2 years in the F/F,V/F, and V/V allele groups was 62.5%, 100%, and 100%, respectively. The OS in the F/F allele group was found to be lower thanin the other 2 allele groups (p=0.01).Conclusion: The distribution of gene polymorphisms in our study group was similar to those of previous studies. While ORRwas similar between the groups, our results highlight a lower OS in F/F patients compared to other allele groups of FcγRIIIA.